93 related articles for article (PubMed ID: 18703347)
1. Re: Prognostic value of FDG uptake in early stage non-small cell lung cancer.
Chong CF
Eur J Cardiothorac Surg; 2008 Oct; 34(4):932; author reply 932-3. PubMed ID: 18703347
[No Abstract] [Full Text] [Related]
2. Prognostic value of fluorodeoxyglucose uptake in non-small cell lung cancer: time for standardization and validation.
Dooms C; Vansteenkiste J
J Thorac Oncol; 2010 May; 5(5):583-4. PubMed ID: 20421763
[No Abstract] [Full Text] [Related]
3. Quantification of 18F-FDG uptake in non-small cell lung cancer: a feasible prognostic marker?
Buck AK; Glatting G; Reske SN
J Nucl Med; 2004 Aug; 45(8):1274-6. PubMed ID: 15299047
[No Abstract] [Full Text] [Related]
4. Use of anthropometric factors in 18F-FDG PET bone marrow SUVs.
Thie JA
J Nucl Med; 2006 Nov; 47(11):1901-2; author reply 1902. PubMed ID: 17079825
[No Abstract] [Full Text] [Related]
5. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
Hanin FX; Lonneux M; Cornet J; Noirhomme P; Coulon C; Distexhe J; Poncelet AJ
Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma.
Ahuja V; Coleman RE; Herndon J; Patz EF
Cancer; 1998 Sep; 83(5):918-24. PubMed ID: 9731895
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: a review.
Pillot G; Siegel BA; Govindan R
J Thorac Oncol; 2006 Feb; 1(2):152-9. PubMed ID: 17409845
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
[TBL] [Abstract][Full Text] [Related]
9. 18F-deoxyglucose uptake in stage I non-small-cell lung cancer: time to move to randomized trials.
De Ruysscher D
J Thorac Oncol; 2014 Jan; 9(1):5-6. PubMed ID: 24346088
[No Abstract] [Full Text] [Related]
10. Prognostic value of posttreatment [18F] fluorodeoxyglucose uptake of primary non-small cell lung carcinoma treated with radiation therapy with or without chemotherapy: a brief review.
Kased N; Erasmus JJ; Komaki R; Cox JD
J Thorac Oncol; 2008 May; 3(5):534-8. PubMed ID: 18449010
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer.
Zhang ZJ; Chen JH; Meng L; Du JJ; Zhang L; Liu Y; Dai HH
Chin Med J (Engl); 2007 Jan; 120(2):125-31. PubMed ID: 17335654
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study.
Higashi K; Ito K; Hiramatsu Y; Ishikawa T; Sakuma T; Matsunari I; Kuga G; Miura K; Higuchi T; Tonami H; Yamamoto I
J Nucl Med; 2005 Feb; 46(2):267-73. PubMed ID: 15695786
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer.
Patz EF; Connolly J; Herndon J
AJR Am J Roentgenol; 2000 Mar; 174(3):769-74. PubMed ID: 10701623
[TBL] [Abstract][Full Text] [Related]
15. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer.
Hicks RJ; Kalff V; MacManus MP; Ware RE; Hogg A; McKenzie AF; Matthews JP; Ball DL
J Nucl Med; 2001 Nov; 42(11):1596-604. PubMed ID: 11696627
[TBL] [Abstract][Full Text] [Related]
16. 18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer.
Laking G; Price P
Thorax; 2001 Sep; 56 Suppl 2(Suppl 2):ii38-44. PubMed ID: 11514705
[No Abstract] [Full Text] [Related]
17. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Dittmann H; Langen HJ; Bares R
Lung Cancer; 2007 Feb; 55(2):165-71. PubMed ID: 17129635
[TBL] [Abstract][Full Text] [Related]
18. [18FDG-PET applications in thoracic oncology].
Bury T; Daenen F; Duysinx B; Bartsch P; Corhay JL
Rev Mal Respir; 2001 Dec; 18(6 Pt 1):623-30. PubMed ID: 11924183
[TBL] [Abstract][Full Text] [Related]
19. Application of a neural network to improve nodal staging accuracy with 18F-FDG PET in non-small cell lung cancer.
Vesselle H; Turcotte E; Wiens L; Haynor D
J Nucl Med; 2003 Dec; 44(12):1918-26. PubMed ID: 14660717
[TBL] [Abstract][Full Text] [Related]
20. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification.
Hicks RJ; Kalff V; MacManus MP; Ware RE; McKenzie AF; Matthews JP; Ball DL
J Nucl Med; 2001 Nov; 42(11):1605-13. PubMed ID: 11696628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
